Sabin株脊髓灰质炎灭活疫苗与常规婴儿疫苗同时或分开接种的免疫原性与耐受性:多中心随机对照扩展III期非劣效试验
该多中心开放标签随机对照扩展III期非劣效试验纳入孟加拉国和巴基斯坦1442名6-8周健康婴儿,比较sIPV与常规婴儿疫苗同时接种(C1、C2组)与分开接种(S1、S2组)的免疫原性和耐受性。结果显示同时接种组与分开接种组脊髓灰质炎病毒I、II、III型血清阳转率相近,7天内不良事件发生率两组均较高(92.8% vs 95.5%),表明按3剂基础免疫程序同时接种sIPV具有良好安全性和免疫原性。
要点
- sIPV与常规婴儿疫苗同时接种的血清阳转率非劣效于分开接种。
- 同时接种组与分开接种组7天内不良事件发生率分别为92.8%和95.5%。
- 该研究支持按3剂基础免疫程序同时接种sIPV。
核心结论
- sIPV与常规婴儿疫苗同时接种按3剂基础免疫程序具有良好的安全性和免疫原性。
研究设计与样本
- 多国多中心开放标签随机对照扩展III期非劣效临床试验,纳入孟加拉国和巴基斯坦1442名6-8周健康婴儿,随机分为同时接种组1(C1)、同时接种组2(C2)、分开接种组1(S1)和分开接种组2(S2)。
主要发现
- 接种后PV I血清阳转率C1组90.3%(306/339)、S1组87.0%(261/300);PV II血清阳转率C1组91.7%(311/339)、S1组91.3%(274/300);PV III血清阳转率C1组86.4%(293/339)、S1组92.3%(277/300)。
- 接种后7天内报告的不良反应发生率在同时接种组和分开接种组分别为92.8%和95.5%。
关键数值与推荐
- 非劣效性判定标准为血清阳转率差(同时接种组减分开接种组)的95%置信区间下限大于-10%。
临床怎么用
- 预防医学与公共卫生医生可参考本试验结果,在婴儿常规免疫程序中考虑将sIPV与其它常规疫苗同时接种。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral poliovirus vaccine (OPV) has been reported to cause vaccine-derived poliovirus and vaccine-associated paralytic poliomyelitis, and the limited global supply of conventional IPV has led many countries to rely on fractional-dose IPV regimens alongside OPV. The current study aims to assess the sIPV safety and immunogenicity when given concurrently with or in a staggered manner with routine immunization. METHODS: A multi-country, multi-center, open-label, randomized controlled, extended phase III non-inferiority clinical trial was conducted with 1442 healthy infants aged 6-8 weeks from Bangladesh and Pakistan enrolled and randomized into four groups, i.e., co-administration group 1 (group C1), co-administration group 2 (group C2), staggered administration group 1 (group S1) and staggered administration group 2 (group S2). Antibody levels were determined using the collected sera for immunogenicity evaluation. The difference in seroconversion rates between the coadministration group and the staggered administration group is compared using the Cochran-Mantel-Haenszel χ2 (CMH-χ2) test, stratified by study site. Non-inferiority is concluded if the lower bound of the 95% confidence interval (CI) for the rate difference (coadministration group minus staggered administration group) is greater than -10%. The trial was registered prior to patient enrollment at clinicaltrials.gov (NCT05850364), and the protocol and statistical analysis plan are available at https://clinicaltrials.gov/study/NCT05850364. The trial is closed to new participants. FINDINGS: The post-vaccination seroconversion rates for PV I were 90.3% (306/339) in group C1 and 87.0% (261/300) in group S1, for PV II, 91.7% (311/339) in group C1 and 91.3% (274/300) in group S1 and for PV III, 86.4% (293/339) in group C1 and 92.3% (277/300) in group S1. Among adverse reactions (ARs) reported within 7 days of vaccination, the incidence was similarly high in both the co-administration and staggered vaccination groups (92.8% vs. 95.5%). INTERPRETATION: Our results demonstrated favorable safety and immunogenicity of co-administration of sIPV with other routine infant vaccines according to a 3-dose primary immunization schedule.
引用
- Islam MA, Zehra SM, Kazi Z, et al. A multi-center, open-labelled, randomized controlled extended phase III non-inferiority clinical trial to evaluate the immunogenicity and tolerability of poliomyelitis vaccine (Vero cells), inactivated, Sabin strains administered with or without routine infant vaccines. Vaccine. 2026. PMID: 42659917. doi:10.1016/j.vaccine.2026.129095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。